# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jefferies analyst David Stanton upgrades Mesoblast (NASDAQ:MESO) from Hold to Buy.
Cantor Fitzgerald analyst Louise Chen reiterates Mesoblast (NASDAQ:MESO) with a Overweight.
Piper Sandler analyst Edward Tenthoff upgrades Mesoblast (NASDAQ:MESO) from Neutral to Overweight and raises the price targe...